{"groups":[{"description":"Participants received lenvatinib 18 milligrams (mg) administered orally, once daily in each 21-day cycle, plus everolimus 5 mg administered orally, once daily in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.","id":"FG000","title":"Lenvatinib 18 mg Plus Everolimus 5 mg"},{"description":"Participants received lenvatinib 20 mg administered orally, once daily in each 21-day cycle, plus pembrolizumab 200 mg administered intravenously, every 3 weeks in each 21-day cycle until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.","id":"FG001","title":"Lenvatinib 20 mg Plus Pembrolizumab 200 mg"},{"description":"Participants received sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment until participant had disease progression, development of unacceptable toxicity, participant request, withdrawal of consent.","id":"FG002","title":"Sunitinib 50 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"97"},{"groupId":"FG002","numSubjects":"174"}],"type":"Radiological Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"22"}],"type":"Clinical Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"41"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"23"}],"type":"Subject Choice"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"3"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"112"},{"groupId":"FG001","numSubjects":"142"},{"groupId":"FG002","numSubjects":"67"}],"type":"Treatment Ongoing at Cutoff Date"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"17"}],"type":"Randomized but not treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"357"},{"groupId":"FG001","numSubjects":"355"},{"groupId":"FG002","numSubjects":"357"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"355"},{"groupId":"FG001","numSubjects":"352"},{"groupId":"FG002","numSubjects":"340"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"357"},{"groupId":"FG001","numSubjects":"355"},{"groupId":"FG002","numSubjects":"357"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 1417 participants were screened, of which, 1069 were randomized. Of the 1069 randomized, 1047 participants were treated in the study.","recruitmentDetails":"Participants took part in the study at 181 investigative sites in Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom of Great Britain and Northern Ireland, the United States of America, Australia, Czechia, Israel, Japan, Korea, Russian Federation, from 13 October 2016 to 28 August 2020 (date of data cutoff for the primary analysis of PFS and second interim analysis of Overall Survival)."}